Neuralink, Synchron, and the BCI Industry

Founded in 2016 by Elon Musk and a team of neuroscientists and engineers, Neuralink develops the high-bandwidth, fully implanted N1 system. The N1 has 1,024 electrodes distributed across 64 ultra-thin polymer threads, robotically inserted by the dedicated R1 surgical robot to avoid manual placement.

The first human implant under FDA IDE took place in January 2024 in the PRIME trial. Participants have demonstrated cursor control, text entry, video-game play, and CAD-software interaction. As of late 2025, Neuralink had publicly disclosed multiple PRIME participants and opened the CONVOY trial for robotic-arm control.

Adjacent Neuralink programs include Blindsight (visual cortex stimulation for restoration of vision in fully blind users) and speech decoding. Disclosed valuation in 2025 funding rounds exceeded USD 9 billion.

Synchron's Stentrode is delivered through the jugular vein and parked in the superior sagittal sinus over the motor cortex, requiring no craniotomy. It records local field potentials from ~16 channels - lower bandwidth than intracortical arrays but with a dramatically simpler regulatory and surgical pathway.

Synchron holds FDA Breakthrough Device designation and has implanted patients in both the US COMMAND trial and earlier Australian SWITCH trial. The company has demonstrated text entry, smart-home control, and integration with consumer devices (Apple Vision Pro support announced in 2024).

Investors include Khosla Ventures, Bezos Expeditions, and Gates Frontier. The deliberately minimally invasive bet positions Synchron as a likely first-to-PMA candidate among high-profile BCI startups.

Paradromics (Connexus, 1,600+ channels per implant, multi-implant systems planned) targets high-bandwidth speech restoration; first human implant occurred in 2025.

Precision Neuroscience (Layer 7 cortical interface, 1,024+ channels in a thin-film array placed on the cortical surface, fully reversible) received FDA 510(k) clearance for its electrode array in 2025 - the first commercial BCI hardware clearance of its class.

Blackrock Neurotech (Utah array veterans with over two decades of human-implant experience) is developing the Neuralace next-generation high-density system.

Inbrain Neuroelectronics (graphene-based electrodes, partnership with Merck KGaA) is in early human studies in Manchester, UK.

Onward Medical pioneered targeted epidural spinal stimulation (ARC-EX, ARC-IM) that has restored walking in people with motor-complete spinal cord injury; FDA De Novo authorisation was granted for ARC-EX in 2024.

Science Corporation (founded by former Neuralink president Max Hodak) is developing the Prima retinal implant alongside cortical BCI work.

Motif Neurotech is developing minimally invasive neuromodulation for depression and other psychiatric indications.

Chinese players, including NeuraMatrix and StairMed, are advancing rapidly under different regulatory regimes; StairMed announced a successful human Neucyber BCI implant in 2024.

Invasiveness versus bandwidth is the dominant trade-off. Stentrodes are delivered without open skull surgery but cap out at low channel counts; intracortical arrays read single units but require craniotomy. Surface arrays (Precision, Inbrain) sit in the middle.

Business-model differences run in parallel: medical-device-first companies (Synchron, Precision, Onward, Inbrain) move through narrow FDA-cleared indications and reimbursement codes; platform-first companies (Neuralink, Paradromics) aim for higher-capability systems with broader claims and longer regulatory paths.

Software stacks - especially decoders, calibration tooling, and clinical-trial data infrastructure - are increasingly viewed as the harder defensible moat over the next decade as electrode-fabrication knowledge diffuses.